Compare GSK plc (GSK) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Norfolk Southern Corporation — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Norfolk Southern Corporation trades at $317.62 (market cap $71.20B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Norfolk Southern Corporation for 33 Days on average.
| GSK | NSC | |
|---|---|---|
Market Cap | $91.88B | $71.20B |
Volume | 7,730,529 | 555,248 |
Sector | Health | Industrials |
52-Week High | $61.18 | $352.98 |
52-Week Low | $43.24 | $278.19 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $111.88B | $86.75B |
Dividend Yield | 3.9% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Norfolk Southern (NSC) trades at $317.79, up 1.47% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected on October 22, 2026. Fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though revenue growth is modest. The proposed merger with Union Pacific is a key development, gaining regulatory and customer support.
The outlook is positive, supported by earnings momentum and merger potential, offering upside to the $361.86 consensus price target. Risks include merger approval uncertainty, fuel cost pressures noted in September 2026, and a high P/E ratio of 27.05. Institutional interest remains strong, with recent investments from firms like Bank of America.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
